Marta Salichs
Research Subjects
Marta Salichs has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Josep Homedes
R&D Department Ecuphar Veterinaria SLU (Animalcare Group) Sant Cugat del Vallès Barcelona Spain
7 shared publications - Shea Beasley
Sheaps Oy Ojakkala Finland
3 shared publications - Cristina Costa-Farré
Departamento de Medicina y Cirugía Animales, Facultat de Veterinària, Universitat Autònoma de Barcelona, Travessera dels Turons, Cerdanyola del Vallés, Barcelona, Spain
2 shared publications Alix Simons
YUN NV Niel Belgium
1 shared publication- Anabel Blasco-Moreno
Servei d’Estadística Aplicada, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain
1 shared publication Anabel Blasco‐Moreno
Servei d'Estadística Aplicada Universitat Autònoma de Barcelona Bellaterra Barcelona Spain
1 shared publication
Latest Publications
- Open Access
- 9 August 2026
- Published by Wiley in Veterinary Record
Single‐dose enflicoxib versus a 7‐day course of firocoxib for postoperative pain control in dogs undergoing orthopaedic surgery: A multicentre, randomised, masked, non‐inferiority study
Background: Perioperative analgesia is essential in dogs undergoing orthopaedic surgery, and enflicoxib's long duration makes single‐dose administration attractive. Methods: A prospective, multicentre, randomised, masked trial compared enflicoxib (8 mg/kg) given 24 hours before surgery with firocoxib (5 mg/kg) given daily for 7 days. Two hundred and sixteen dogs were enrolled. Pain was assessed using the short form of the Glasgow composite pain scale (SF‐GCPS) at predefined timepoints from 2 hours to 7 days after surgery. Inflammation was scored using a visual analogue scale, and owners evaluated demeanour, mobility and perceived analgesic quality. The primary efficacy endpoint was the area under the curve of the SF‐GCPS scores during the first 48 hours after surgery (SF‐GCPS AUC 2–48 h ). Treatment success was also calculated. Results: Enflicoxib was non‐inferior to firocoxib for SF‐GCPS AUC 2–48 h . Early postoperative inflammation (2–8 hours) was significantly lower with enflicoxib. Pain scores at individual timepoints, treatment success and owner assessments were similar between groups. Limitations: The non‐inferiority margin was not formally validated. Conclusions: A single preoperative dose of enflicoxib provided safe, effective control of postoperative pain and inflammation associated with orthopaedic surgery in dogs and represents a practical perioperative non‐steroidal anti‐inflammatory drug option.
- 9 August 2026
- Published by Wiley in Veterinary Record
Open AccessSingle‐dose enflicoxib versus a 7‐day course of firocoxib for postoperative pain control in dogs undergoing orthopaedic surgery: A multicentre, randomised, masked, non‐inferiority study
Background: Perioperative analgesia is essential in dogs undergoing orthopaedic surgery, and enflicoxib's long duration makes single‐dose administration attractive. Methods: A prospective, multicentre, randomised, masked trial compared enflicoxib (8 mg/kg) given 24 hours before surgery with firocoxib (5 mg/kg) given daily for 7 days. Two hundred and sixteen dogs were enrolled. Pain was assessed using the short form of the Glasgow composite pain scale (SF‐GCPS) at predefined timepoints from 2 hours to 7 days after surgery. Inflammation was scored using a visual analogue scale, and owners evaluated demeanour, mobility and perceived analgesic quality. The primary efficacy endpoint was the area under the curve of the SF‐GCPS scores during the first 48 hours after surgery (SF‐GCPS AUC 2–48 h ). Treatment success was also calculated. Results: Enflicoxib was non‐inferior to firocoxib for SF‐GCPS AUC 2–48 h . Early postoperative inflammation (2–8 hours) was significantly lower with enflicoxib. Pain scores at individual timepoints, treatment success and owner assessments were similar between groups. Limitations: The non‐inferiority margin was not formally validated. Conclusions: A single preoperative dose of enflicoxib provided safe, effective control of postoperative pain and inflammation associated with orthopaedic surgery in dogs and represents a practical perioperative non‐steroidal anti‐inflammatory drug option.
- Open Access
- 19 June 2026
- Published by Wiley in Veterinary Dermatology
- Vol. 37 (5) , 818-826
Clinical Efficacy of Probiotic‐Based Ear Drops Containing Lactobacilli in Canine Erythroceruminous Otitis Externa: An Open Label, Multicentre Study
Background: Otitis externa (OE) represents a common clinical problem in dogs. Allergic dogs exhibit reduced diversity of the otic microbiota, and inflammation‐induced changes in the ear canal microenvironment result in a further decline in microbial biodiversity. Probiotics have demonstrated efficacy in certain dermatological conditions, including atopic dermatitis, which is, in turn, the leading primary cause of OE in dogs. Objectives: To evaluate the efficacy of probiotic‐based ear drops in controlling clinical signs related to erythroceruminous non‐infected OE in dogs. Animals: Thirty‐seven privately owned dogs with non‐infected OE. Materials and Methods: Dogs received probiotic‐based ear drops topically every 48 h for 28 days, in accordance with the manufacturer's instructions. Assessments were performed at enrolment (Day [D]0), D14 and D28, including cytological evaluation of ear discharge, pruritus intensity (PVAS, pruritis Visual Analogue Scale), severity of otic lesions (OTIS3, 0–3 Otitis Index Score) and a quality‐of‐life survey (QoL). Results: At enrolment (D0), mean OTIS3 and PVAS scores for all included animals were 5.11 ± 1.20 and 4.93 ± 1.51, respectively. Both scores decreased significantly by D28, to 1.66 ± 1.75 and 2.09 ± 2.03, respectively. Clinical improvement was evident regardless of concomitant medication use or the type of micro‐organism's overgrowth observed during the initial cytological assessment. Owner‐reported QoL improved in 80% of the dogs. Conclusion and Clinical Relevance: These probiotic‐based ear drops may be a useful adjunctive therapy in cases of canine non‐infectious erythroceruminous OE.
- 19 June 2026
- Published by Wiley in Veterinary Dermatology
- Vol. 37 (5) , 818-826
Open AccessClinical Efficacy of Probiotic‐Based Ear Drops Containing Lactobacilli in Canine Erythroceruminous Otitis Externa: An Open Label, Multicentre Study
Background: Otitis externa (OE) represents a common clinical problem in dogs. Allergic dogs exhibit reduced diversity of the otic microbiota, and inflammation‐induced changes in the ear canal microenvironment result in a further decline in microbial biodiversity. Probiotics have demonstrated efficacy in certain dermatological conditions, including atopic dermatitis, which is, in turn, the leading primary cause of OE in dogs. Objectives: To evaluate the efficacy of probiotic‐based ear drops in controlling clinical signs related to erythroceruminous non‐infected OE in dogs. Animals: Thirty‐seven privately owned dogs with non‐infected OE. Materials and Methods: Dogs received probiotic‐based ear drops topically every 48 h for 28 days, in accordance with the manufacturer's instructions. Assessments were performed at enrolment (Day [D]0), D14 and D28, including cytological evaluation of ear discharge, pruritus intensity (PVAS, pruritis Visual Analogue Scale), severity of otic lesions (OTIS3, 0–3 Otitis Index Score) and a quality‐of‐life survey (QoL). Results: At enrolment (D0), mean OTIS3 and PVAS scores for all included animals were 5.11 ± 1.20 and 4.93 ± 1.51, respectively. Both scores decreased significantly by D28, to 1.66 ± 1.75 and 2.09 ± 2.03, respectively. Clinical improvement was evident regardless of concomitant medication use or the type of micro‐organism's overgrowth observed during the initial cytological assessment. Owner‐reported QoL improved in 80% of the dogs. Conclusion and Clinical Relevance: These probiotic‐based ear drops may be a useful adjunctive therapy in cases of canine non‐infectious erythroceruminous OE.
- Open Access
- 8 May 2026
- Published by Wiley in Veterinary Dermatology
- Vol. 37 (4) , 534-540
Probiotic Engraftment and Suppression of Canine Otitis Externa Pathogens by Probiotic Ear Drops
Background: Lactobacillaceae have shown promise with their potential to outcompete pathogens and restore a healthy microbial balance in otitis externa (OE). Hypothesis/Objectives: This study aimed to evaluate the presence of viable Lactobacillaceae over time and in vitro ability to inhibit growth of common OE pathogens. Animals: Fifteen healthy dogs were enrolled and randomised into five groups ( n = 3 per group) to receive six probiotic ear drops containing live Lactiplantibacillus plantarum YUN‐V2.0 and Lacticaseibacillus rhamnosus YUN‐S1.0. Materials and Methods: Ear swabs were taken 24, 48, 72, 96 h and 7 days post single application for culturing. For pathogen inhibition, clinical isolates of Pseudomonas aeruginosa , Staphylococcus pseudintermedius and Malassezia pachydermatis were tested against the probiotic ear drop and antimicrobial disks of florfenicol 30 μg, gentamicin 30 μg, marbofloxacin 5 μg, miconazole 10 μg, neomycin 120 μg and terbinafine 1.5 μg. Results: A relatively basal low abundance of commensal and Lactobacillaceae micro‐organisms was detected (1.34 × 10 3 colony‐forming units [cfu]/mL). At 24 h post‐application, Lactobacillaceae increased significantly (2.3 × 10 6 cfu/mL; p < 0.001), and remained above 10 5 cfu/mL at 1 week post‐application (1.6 × 10 5 cfu/mL). Lactobacilli demonstrated better growth inhibition of P. aeruginosa than gentamicin and marbofloxacin, and of S. pseudintermedius than gentamicin, neomycin and marbofloxacin. For M. pachydermatis similar growth inhibition versus miconazole and terbinafine was observed. Conclusions and Clinical Relevance: These results suggest that probiotic strains exhibit excellent retention and can inhibit the growth of S. pseudintermedius , P. aeruginosa , and M. pachydermatis .
- 8 May 2026
- Published by Wiley in Veterinary Dermatology
- Vol. 37 (4) , 534-540
Open AccessProbiotic Engraftment and Suppression of Canine Otitis Externa Pathogens by Probiotic Ear Drops
Background: Lactobacillaceae have shown promise with their potential to outcompete pathogens and restore a healthy microbial balance in otitis externa (OE). Hypothesis/Objectives: This study aimed to evaluate the presence of viable Lactobacillaceae over time and in vitro ability to inhibit growth of common OE pathogens. Animals: Fifteen healthy dogs were enrolled and randomised into five groups ( n = 3 per group) to receive six probiotic ear drops containing live Lactiplantibacillus plantarum YUN‐V2.0 and Lacticaseibacillus rhamnosus YUN‐S1.0. Materials and Methods: Ear swabs were taken 24, 48, 72, 96 h and 7 days post single application for culturing. For pathogen inhibition, clinical isolates of Pseudomonas aeruginosa , Staphylococcus pseudintermedius and Malassezia pachydermatis were tested against the probiotic ear drop and antimicrobial disks of florfenicol 30 μg, gentamicin 30 μg, marbofloxacin 5 μg, miconazole 10 μg, neomycin 120 μg and terbinafine 1.5 μg. Results: A relatively basal low abundance of commensal and Lactobacillaceae micro‐organisms was detected (1.34 × 10 3 colony‐forming units [cfu]/mL). At 24 h post‐application, Lactobacillaceae increased significantly (2.3 × 10 6 cfu/mL; p < 0.001), and remained above 10 5 cfu/mL at 1 week post‐application (1.6 × 10 5 cfu/mL). Lactobacilli demonstrated better growth inhibition of P. aeruginosa than gentamicin and marbofloxacin, and of S. pseudintermedius than gentamicin, neomycin and marbofloxacin. For M. pachydermatis similar growth inhibition versus miconazole and terbinafine was observed. Conclusions and Clinical Relevance: These results suggest that probiotic strains exhibit excellent retention and can inhibit the growth of S. pseudintermedius , P. aeruginosa , and M. pachydermatis .
- Open Access
- 1 March 2026
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 264 (3) , 288-296
Efficacy of enflicoxib for postoperative pain and inflammation in soft tissue surgery in dogs: a multicenter and randomized clinical field trial
Objective: To demonstrate that a single dose of enflicoxib is noninferior to daily carprofen for the control of pain and inflammation in dogs undergoing soft tissue surgery. Methods: A prospective, multisite, blinded, randomized, controlled, parallel-group, noninferiority field study was performed to assess the efficacy and safety of enflicoxib in the control of pain and inflammation associated with soft tissue surgery. Two hundred fifteen dogs were randomized to receive 8 mg/kg of enflicoxib PO the day before surgery or 4 mg/kg of carprofen SC at induction and PO daily for 5 days. Veterinarians assessed efficacy with the short form of the Glasgow Composite Pain Scale (SF-GCPS) at 2, 5, 8, and 24 hours and 2, 3, and 5 days after surgery. The visual analog scale was used to assess inflammation. Demeanor, analgesia, and mobility were assessed daily by the owners. Results: Enflicoxib was noninferior to carprofen in the SF-GCPS area under the curve for the first 48 hours. Inflammation and SF-GCPS total scores were within the clinically relevant margin at each time point. No differences were observed in inflammation or in the owner assessment. Conclusions: Enflicoxib administered 24 hours before surgery is safe and efficacious for the control of postoperative pain associated with soft tissue surgery. Clinical Relevance: A single preoperative dose of enflicoxib is an alternative for postoperative management in dogs undergoing soft tissue surgery, offering a simplified treatment regimen without compromising outcomes.
- 1 March 2026
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 264 (3) , 288-296
Open AccessEfficacy of enflicoxib for postoperative pain and inflammation in soft tissue surgery in dogs: a multicenter and randomized clinical field trial
Objective: To demonstrate that a single dose of enflicoxib is noninferior to daily carprofen for the control of pain and inflammation in dogs undergoing soft tissue surgery. Methods: A prospective, multisite, blinded, randomized, controlled, parallel-group, noninferiority field study was performed to assess the efficacy and safety of enflicoxib in the control of pain and inflammation associated with soft tissue surgery. Two hundred fifteen dogs were randomized to receive 8 mg/kg of enflicoxib PO the day before surgery or 4 mg/kg of carprofen SC at induction and PO daily for 5 days. Veterinarians assessed efficacy with the short form of the Glasgow Composite Pain Scale (SF-GCPS) at 2, 5, 8, and 24 hours and 2, 3, and 5 days after surgery. The visual analog scale was used to assess inflammation. Demeanor, analgesia, and mobility were assessed daily by the owners. Results: Enflicoxib was noninferior to carprofen in the SF-GCPS area under the curve for the first 48 hours. Inflammation and SF-GCPS total scores were within the clinically relevant margin at each time point. No differences were observed in inflammation or in the owner assessment. Conclusions: Enflicoxib administered 24 hours before surgery is safe and efficacious for the control of postoperative pain associated with soft tissue surgery. Clinical Relevance: A single preoperative dose of enflicoxib is an alternative for postoperative management in dogs undergoing soft tissue surgery, offering a simplified treatment regimen without compromising outcomes.
- Open Access
- 15 July 2025
- Published by Elsevier in Research in Veterinary Science
- Vol. 193, 105804
Assessment of enflicoxib efficacy in the control of postoperative pain and inflammation in dogs undergoing orthopaedic surgery. A pilot randomised clinical trial
- 15 July 2025
- Published by Elsevier in Research in Veterinary Science
- Vol. 193, 105804
Open AccessAssessment of enflicoxib efficacy in the control of postoperative pain and inflammation in dogs undergoing orthopaedic surgery. A pilot randomised clinical trial
- Open Access
- 8 October 2024
- Published by Wiley in Veterinary Dermatology
- Vol. 36 (1) , 74-82
Efficacy of an oral chew containing fibre and Bacillus velezensis C‐3102 in the management of anal sac impaction in dogs
Background: Anal sac impaction is common in dogs. Manual expression may be effective, yet recurrence can be problematic. To facilitate physiological emptying of the sacs, it is important to maintain bulky stool consistency. Objectives: The study evaluated if supplementation with a complementary feed product formulated as a chew containing Bacillus velezensis C‐3102 and fibre sources, reduced anal sac impaction recurrence. Animals: Thirty‐five client‐owned dogs with anal sac impaction were enrolled. Materials and Methods: Prospective, randomised, negative controlled field clinical trial with 22 dogs receiving the chew orally for 90 consecutive days and 13 dogs with no treatment. Dogs were evaluated on Day (D) 30, 60, 90 and 120 for the presence of clinical signs of anal sac impaction and the need to empty the sacs. Any animal that required manual expression of the sacs was classified as a failure and was withdrawn from the study. Results: The cumulative percentage of failures in the untreated group increased steadily from the first follow‐up visit on D30 (15%) to the last visit on D120 (61.5%). However, in the group receiving the chew the cumulative percentage of failures increased at a much slower rate and stabilised at 19% from the D90 visit (last administration day) until the end of the study on D120, with statistically significant differences ( p = 0.025). Animals receiving the chew also showed reduction in clinical signs. Conclusion and Clinical Relevance: The probiotic and fibre chew was a safe and effective management option for recurrent anal sac impaction in dogs.
- 8 October 2024
- Published by Wiley in Veterinary Dermatology
- Vol. 36 (1) , 74-82
Open AccessEfficacy of an oral chew containing fibre and Bacillus velezensis C‐3102 in the management of anal sac impaction in dogs
Background: Anal sac impaction is common in dogs. Manual expression may be effective, yet recurrence can be problematic. To facilitate physiological emptying of the sacs, it is important to maintain bulky stool consistency. Objectives: The study evaluated if supplementation with a complementary feed product formulated as a chew containing Bacillus velezensis C‐3102 and fibre sources, reduced anal sac impaction recurrence. Animals: Thirty‐five client‐owned dogs with anal sac impaction were enrolled. Materials and Methods: Prospective, randomised, negative controlled field clinical trial with 22 dogs receiving the chew orally for 90 consecutive days and 13 dogs with no treatment. Dogs were evaluated on Day (D) 30, 60, 90 and 120 for the presence of clinical signs of anal sac impaction and the need to empty the sacs. Any animal that required manual expression of the sacs was classified as a failure and was withdrawn from the study. Results: The cumulative percentage of failures in the untreated group increased steadily from the first follow‐up visit on D30 (15%) to the last visit on D120 (61.5%). However, in the group receiving the chew the cumulative percentage of failures increased at a much slower rate and stabilised at 19% from the D90 visit (last administration day) until the end of the study on D120, with statistically significant differences ( p = 0.025). Animals receiving the chew also showed reduction in clinical signs. Conclusion and Clinical Relevance: The probiotic and fibre chew was a safe and effective management option for recurrent anal sac impaction in dogs.
- Open Access
- 4 October 2023
- Published by Springer Nature in Parasites & Vectors
- Vol. 16 (1) , 1-17
A blinded, randomized and controlled multicenter clinical trial to assess the efficacy and safety of Leisguard® as an immunotherapeutic treatment for healthy Leishmania infantum-seropositive dogs
Background: Domperidone (Leisguard®) is an immunomodulatory drug used as a preventive measure in healthy dogs. However, no studies have been published in healthyLeishmania infantum-seropositive dogs. The aim of this study was to evaluate the clinical efficacy and safety of domperidone as immunotherapy inLeishmania-seropositive healthy dogs.Methods: Sixty-seven dogs were treated with domperidone at 0.5 mg/kg and 44 dogs received placebo, once daily for 4 consecutive weeks. Monthly treatments were repeated every 4 months until the end of the 1-year follow-up period. Veterinary examinations were performed on days 0, 30, 120, 150, 240, 270 and 360. Samples of blood and urine were collected on days 0, 120, 240 and 360 for routine laboratory tests and quantitative in-house ELISA for the detection ofL. infantum-specific antibodies. Furthermore,Leishmaniareal-time PCR and IFN-γ ELISA were performed at day 0 and the end of the study. Dogs that developed disease were withdrawn from the study and classified as sick dogs. Adverse drug reactions were reported.Results: Thirty dogs developed disease during the follow-up period: 13/67 (19.4%) in the group treated with domperidone and 17/44 (38.6%) in the placebo-treated group (P = 0.03). Low-seropositive dogs treated with domperidone (4/40, 9.1%) were significantly less likely to develop disease compared to low-seropositive dogs treated with placebo (7/24, 29.2%;P = 0.04), while no differences were found between domperidone (9/23, 39.1%) and placebo (10/20, 50%) in medium- to high-seropositive dogs. At the end of the study, a higher proportion ofLeishmaniaPCR-positive dogs was observed in the placebo-treated group (16/33, 48.5%) compared to the domperidone group (13/51, 25.5%;P = 0.04). Furthermore, low-seropositive dogs treated with domperidone with an increase of IFN-γ concentration presented a higher increase than those treated with placebo at the end of the study. Four dogs treated with domperidone presented self-limiting diarrhea.Conclusions: Healthy dogs with lowL. infantumantibody levels treated with domperidone were less likely to develop disease compared to placebo-treated dogs. Furthermore, domperidone presented a good safety profile.Graphical
- 4 October 2023
- Published by Springer Nature in Parasites & Vectors
- Vol. 16 (1) , 1-17
Open AccessA blinded, randomized and controlled multicenter clinical trial to assess the efficacy and safety of Leisguard® as an immunotherapeutic treatment for healthy Leishmania infantum-seropositive dogs
Background: Domperidone (Leisguard®) is an immunomodulatory drug used as a preventive measure in healthy dogs. However, no studies have been published in healthyLeishmania infantum-seropositive dogs. The aim of this study was to evaluate the clinical efficacy and safety of domperidone as immunotherapy inLeishmania-seropositive healthy dogs.Methods: Sixty-seven dogs were treated with domperidone at 0.5 mg/kg and 44 dogs received placebo, once daily for 4 consecutive weeks. Monthly treatments were repeated every 4 months until the end of the 1-year follow-up period. Veterinary examinations were performed on days 0, 30, 120, 150, 240, 270 and 360. Samples of blood and urine were collected on days 0, 120, 240 and 360 for routine laboratory tests and quantitative in-house ELISA for the detection ofL. infantum-specific antibodies. Furthermore,Leishmaniareal-time PCR and IFN-γ ELISA were performed at day 0 and the end of the study. Dogs that developed disease were withdrawn from the study and classified as sick dogs. Adverse drug reactions were reported.Results: Thirty dogs developed disease during the follow-up period: 13/67 (19.4%) in the group treated with domperidone and 17/44 (38.6%) in the placebo-treated group (P = 0.03). Low-seropositive dogs treated with domperidone (4/40, 9.1%) were significantly less likely to develop disease compared to low-seropositive dogs treated with placebo (7/24, 29.2%;P = 0.04), while no differences were found between domperidone (9/23, 39.1%) and placebo (10/20, 50%) in medium- to high-seropositive dogs. At the end of the study, a higher proportion ofLeishmaniaPCR-positive dogs was observed in the placebo-treated group (16/33, 48.5%) compared to the domperidone group (13/51, 25.5%;P = 0.04). Furthermore, low-seropositive dogs treated with domperidone with an increase of IFN-γ concentration presented a higher increase than those treated with placebo at the end of the study. Four dogs treated with domperidone presented self-limiting diarrhea.Conclusions: Healthy dogs with lowL. infantumantibody levels treated with domperidone were less likely to develop disease compared to placebo-treated dogs. Furthermore, domperidone presented a good safety profile.Graphical
- 1 September 2013
- Published by Oxford University Press (OUP) in Journal of Animal Science
- Vol. 91 (9) , 4469-4475
Efficacy of ketoprofen administered in drinking water at a low dose for the treatment of porcine respiratory disease complex1,2
The purpose of this study was to evaluate the efficacy of an oral solution of ketoprofen administered in drinking water at a lower dose as a complement to antimicrobial therapy in a mild outbreak of porcine respiratory disease complex. The study was performed with 120 pigs with rectal temperature between 39.9 and 41°C and at least 1 sign indicating porcine respiratory disease complex (dyspnea, cough, nasal discharge, or depression). Animals were randomly allocated in 2 groups (treated and control group). Animals in both groups received etiological therapy with doxycycline at 10 mg·kg–1 in drinking water for 5 d. The animals in the treated group also received 1.5 mg·kg–1 of ketoprofen during the first 3 d. The reduction in rectal temperature in the treated group was significantly greater during the days of ketoprofen administration and up to 1 d after the end of treatment (P < 0.05). The percentage of dyspneic animals was significantly less (P < 0.05) in the treated group from d 2 to 5 of the study. Also, a significant improvement regarding depression and cough was seen in the animals of the treated group. No statistically significant (P > 0.05) differences were evidenced in productive variables. In conclusion, oral treatment with ketoprofen at 1.5 mg·kg–1 in combination with antimicrobial therapy was found to be a clinically effective approach in outbreaks of mild porcine respiratory disease complex. Copyright © 2013. American Society of Animal Science .
- 1 September 2013
- Published by Oxford University Press (OUP) in Journal of Animal Science
- Vol. 91 (9) , 4469-4475
Efficacy of ketoprofen administered in drinking water at a low dose for the treatment of porcine respiratory disease complex1,2
The purpose of this study was to evaluate the efficacy of an oral solution of ketoprofen administered in drinking water at a lower dose as a complement to antimicrobial therapy in a mild outbreak of porcine respiratory disease complex. The study was performed with 120 pigs with rectal temperature between 39.9 and 41°C and at least 1 sign indicating porcine respiratory disease complex (dyspnea, cough, nasal discharge, or depression). Animals were randomly allocated in 2 groups (treated and control group). Animals in both groups received etiological therapy with doxycycline at 10 mg·kg–1 in drinking water for 5 d. The animals in the treated group also received 1.5 mg·kg–1 of ketoprofen during the first 3 d. The reduction in rectal temperature in the treated group was significantly greater during the days of ketoprofen administration and up to 1 d after the end of treatment (P < 0.05). The percentage of dyspneic animals was significantly less (P < 0.05) in the treated group from d 2 to 5 of the study. Also, a significant improvement regarding depression and cough was seen in the animals of the treated group. No statistically significant (P > 0.05) differences were evidenced in productive variables. In conclusion, oral treatment with ketoprofen at 1.5 mg·kg–1 in combination with antimicrobial therapy was found to be a clinically effective approach in outbreaks of mild porcine respiratory disease complex. Copyright © 2013. American Society of Animal Science .